drugset / Trial / NCT03895944
ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma
Phase 0
Unknown
18 enrolled
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Clinical study to evaluate safety and pharmacokinetics (primary objectives) and efficacy (secondary objective) of ET190L1-ARTEMIS™2 T-cells in patients with Cluster of Differentiation (CD) 19+ B cell Leukemia and Lymphoma
Timeline
- Start
- 2017-12-06
- Primary completion
- 2019-12-06
- Completion
- 2019-12-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ET190L1 ARTEMIS™ T cells | Cell therapy | 1e+06 cells | Intravenous |
| Subject | ET190L1 ARTEMIS™ T cells | Cell therapy | 3e+06 cells | Intravenous |
| Subject | ET190L1 ARTEMIS™ T cells | Cell therapy | 1e+07 cells | Intravenous |